BI 2536

For research use only. Not for use in humans.

目录号：S1109

Molecular Weight(MW): 521.66

BI-2536是一种有效的Plk1抑制剂，无细胞试验中IC50为0.83 nM。BI-2536可抑制 Bromodomain 4 (BRD4) ，其Kd值为37 nM，并有效地抑制 c-Myc 的表达。BI-2536可诱导凋亡而减弱自噬。Phase 2。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1978.87	现货
5mg	RMB 981.57	现货
10mg	RMB 1704.35	现货
50mg	RMB 5492.59	现货
100mg	RMB 8160.83	现货
大包装	有超大折扣

大剂量询单有大折扣！

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BI 2536发表文献160篇：

Cancer Cell, 2020, 37(3):340-353

PubMed: 32109375 ( click the link to review the publication )

Science, 2019, 364(6447)

PubMed: 31249032 ( click the link to review the publication )

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Nature, 2017, 548(7668):466-470

PubMed: 28759889 ( click the link to review the publication )

Science, 2015, 13;347(6227):aaa2630.

PubMed: 25636800 ( click the link to review the publication )

Cancer Discov, 2014, 4(11):1281-9

PubMed: 25107667 ( click the link to review the publication )

Cell, 2011, 11;147(4):853-67.

PubMed: 22078882 ( click the link to review the publication )

Cancer Cell, 2010, 18(6):641-54

PubMed: 21156286 ( click the link to review the publication )

Mol Cell, 2020, 10.1016/j.molcel.2020.01.023

PubMed: 32035037 ( click the link to review the publication )

Nat Commun, 2020, 29;11(1):2086

PubMed: 32350249 ( click the link to review the publication )

Nat Commun, 2020, 14;11(1):1819

PubMed: 32286328 ( click the link to review the publication )

J Cell Biol, 2020, 1;219(6):e201910019

PubMed: 32271878 ( click the link to review the publication )

Cell Rep, 2020, 17;30(11):3605-3615.e5

PubMed: 32187533 ( click the link to review the publication )

Cell Death Differ, 2020, 19

PubMed: 32203171 ( click the link to review the publication )

Oncogene, 2020, 39(15):3145-3162

PubMed: 32060423 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(3):350-362

PubMed: 32017920 ( click the link to review the publication )

ACS Chem Biol, 2020, 20;15(3):669-674

PubMed: 32004428 ( click the link to review the publication )

J Cell Sci, 2020, 2;jcs.244442

PubMed: 32487663 ( click the link to review the publication )

Biochem Biophys Res Commun, 2020, 521(4):833-839

PubMed: 31708096 ( click the link to review the publication )

DNA Cell Biol, 2020, 10.1089/dna.2019.5002

PubMed: 32182129 ( click the link to review the publication )

Cell Death Differ, 2020, 10.1038

PubMed: 32015503 ( click the link to review the publication )

Cells, 2020, 9(1)

PubMed: 31947732 ( click the link to review the publication )

J Cancer, 2020, 11(11):3274-3287

PubMed: 32231733 ( click the link to review the publication )
Cell Res, 2019, 29(7):562-578

PubMed: 31201382 ( click the link to review the publication )

Mol Cell, 2019, 73(5):915-929

PubMed: 30849395 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3779

PubMed: 31439829 ( click the link to review the publication )

Nat Commun, 2019, 10(1):1473

PubMed: 30931927 ( click the link to review the publication )

Nat Commun, 2019, 10(1):993

PubMed: 30824690 ( click the link to review the publication )

Sci Adv, 2019, 5(8):eaav0318

PubMed: 31803841 ( click the link to review the publication )

Cell Syst, 2019, 8(2):163-167

PubMed: 30797774 ( click the link to review the publication )

Cell Syst, 2019, 9(1):74-92.e8

PubMed: 31302152 ( click the link to review the publication )

EBioMedicine, 2019, 41:244-255

PubMed: 30876762 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):385

PubMed: 31097686 ( click the link to review the publication )

Ther Adv Med Oncol, 2019, 11:1758835919846375

PubMed: 31156720 ( click the link to review the publication )

J Mol Cell Biol, 2019, 10.1093/jmcb/mjz051

PubMed: 31174204 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(9):1615-1627

PubMed: 31227645 ( click the link to review the publication )

FEBS J, 2019, 286(5):963-974

PubMed: 30600590 ( click the link to review the publication )

Mol Cancer Res, 2019, doi: 10

PubMed: 31604847 ( click the link to review the publication )

Lab Invest, 2019, 99(9):1275-1286

PubMed: 30996295 ( click the link to review the publication )

Open Biol, 2019, 9(8):190136

PubMed: 31455158 ( click the link to review the publication )

Mol Cell, 2018, 71(1):117-128

PubMed: 30008317 ( click the link to review the publication )

EMBO Mol Med, 2018, 10(9)

PubMed: 30108112 ( click the link to review the publication )

Theranostics, 2018, 8(10):2884-2895

PubMed: 29774081 ( click the link to review the publication )

Cancer Res, 2018, 78(2):572-583

PubMed: 29180474 ( click the link to review the publication )

Sci Signal, 2018, 11(549)

PubMed: 30254057 ( click the link to review the publication )

Sci Signal, 2018, 11(530)

PubMed: 29764992 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2551-2563

PubMed: 30217967 ( click the link to review the publication )
Mol Cancer Ther, 2018, 17(7):1554-1565

PubMed: 29716963 ( click the link to review the publication )

Mol Cell Proteomics, 2018, 17(12):2434-2447

PubMed: 30217950 ( click the link to review the publication )

J Cell Mol Med, 2018, 22(11):5300-5310

PubMed: 30133120 ( click the link to review the publication )

Hum Gene Ther, 2018, 29(8):886-901

PubMed: 29641320 ( click the link to review the publication )

Sci Rep, 2018, 8(1):3521

PubMed: 29476067 ( click the link to review the publication )

Cell Signal, 2018, 52:137-146

PubMed: 30223016 ( click the link to review the publication )

Cancer Med, 2018, 7(11):5589-5603

PubMed: 30221846 ( click the link to review the publication )

Transl Oncol, 2018, 11(4):852-863

PubMed: 29753186 ( click the link to review the publication )

J Oncol, 2018, 2018:3979527

PubMed: 30631355 ( click the link to review the publication )

Nucleic Acids Res, 2018, 46(20):10724-10739

PubMed: 30202980 ( click the link to review the publication )

Cell Res, 2017, 27(2):274-293

PubMed: 27958289 ( click the link to review the publication )

Mol Cell, 2017, 67(4):579-593

PubMed: 28781233 ( click the link to review the publication )

Mol Cell, 2017, 68(1):210-223e6

PubMed: 28985505 ( click the link to review the publication )

Nat Commun, 2017, 8(1):1506

PubMed: 29138396 ( click the link to review the publication )

Nat Commun, 2017, 8:15289

PubMed: 28474672 ( click the link to review the publication )

Aging Cell, 2017, 16(3):575-584

PubMed: 28345297 ( click the link to review the publication )

Elife, 2017, 6

PubMed: 28994651 ( click the link to review the publication )

FASEB J, 2017, 32(2):625-638

PubMed: 28970258 ( click the link to review the publication )

Cell Chem Biol, 2017, 24(8):1017-1028

PubMed: 28807782 ( click the link to review the publication )

Cell Physiol Biochem, 2017, 43(2):431-444

PubMed: 28922657 ( click the link to review the publication )

Curr Biol, 2017, 27(10):1477-1484

PubMed: 28479321 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(1):3-15

PubMed: 27760837 ( click the link to review the publication )

FEBS J, 2017, 284(23):4035-4050

PubMed: 28985013 ( click the link to review the publication )

J Biol Chem, 2017, 292(36):15028-15038

PubMed: 28739871 ( click the link to review the publication )
Cell Signal, 2017, 39:74-83

PubMed: 28780319 ( click the link to review the publication )

Am J Physiol Cell Physiol, 2017, 313(5):C501-C515

PubMed: 28794108 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 484(4):864-870

PubMed: 28188792 ( click the link to review the publication )

Oncotarget, 2017, 9(13):10920-10933

PubMed: 29541386 ( click the link to review the publication )

Oncotarget, 2017, 8(23):37633-37645

PubMed: 28430578 ( click the link to review the publication )

Nat Chem Biol, 2016, 10.1038/nchembio.2017

PubMed: 26829474 ( click the link to review the publication )

Nat Commun, 2016, 7:11363

PubMed: 27193833 ( click the link to review the publication )

Nat Commun, 2016, 7:10818

PubMed: 26912231 ( click the link to review the publication )

Nat Chem Biol, 2016, 12(6):411-8

PubMed: 27043190 ( click the link to review the publication )

Mol Cancer Ther, 2016, 15(1):48-59

PubMed: 26586723 ( click the link to review the publication )

J Virol, 2016, 90(6):2794-805

PubMed: 26719254 ( click the link to review the publication )

Sci Rep, 2016, 6:19567

PubMed: 26777522 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M116.722751

PubMed: 27226586 ( click the link to review the publication )

J Biol Chem, 2016, 10.1074/jbc.M115.712745

PubMed: 27325694 ( click the link to review the publication )

J Biol Chem, 2016, 291(20):10904-15

PubMed: 27002159 ( click the link to review the publication )

Cell Cycle, 2016, 15(15):2009-18

PubMed: 27249336 ( click the link to review the publication )

PLoS One, 2016, 11(4):e0153818

PubMed: 27097159 ( click the link to review the publication )

Oncotarget, 2016, 7(18):26580-92

PubMed: 27058891 ( click the link to review the publication )

Head Neck, 2016, 10.1002/hed.24349

PubMed: 26713885 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: ( click the link to review the publication )

Nat Cell Biol, 2015, 17(2):113-22

PubMed: 25599390 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(1):31-43

PubMed: 25503564 ( click the link to review the publication )

Nat Cell Biol, 2015, 17(8):1024-35

PubMed: 26192437 ( click the link to review the publication )

Nat Commun, 2015, 6:8388

PubMed: 26399523 ( click the link to review the publication )
Nat Commun, 2015, 10.1038/ncomms8217

PubMed: 26147444 ( click the link to review the publication )

Nat Commun, 2015, 6:6891

PubMed: 25922916 ( click the link to review the publication )

Nat Commun, 2015, 6:8077

PubMed: 26293378 ( click the link to review the publication )

Nat Commun, 2015, 6:6946

PubMed: 25897860 ( click the link to review the publication )

Nat Commun, 2015, 6:10076

PubMed: 26647647 ( click the link to review the publication )

Nat Commun, 2015, 6:10072

PubMed: 26656453 ( click the link to review the publication )

Cancer Res, 2015, 75(2):405-14

PubMed: 25480943 ( click the link to review the publication )

J Control Release, 2015, 204:20-9

PubMed: 25681050 ( click the link to review the publication )

J Control Release, 2015, 204:20-29

PubMed: ( click the link to review the publication )

Cancer Lett, 2015, 357(2):591-601

PubMed: 25524551 ( click the link to review the publication )

Mol Oncol, 2015, 9(2):527-43

PubMed: 25454348 ( click the link to review the publication )

Mol Cell Proteomics, 2015, 14(4):946-60

PubMed: 25659891 ( click the link to review the publication )

J Neurochem, 2015, 10.1111/jnc.13085

PubMed: 25727910 ( click the link to review the publication )

J Biol Chem, 2015, 290(5):3033-44

PubMed: 25505268 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29617-28

PubMed: 26468278 ( click the link to review the publication )

Mol Biol Cell, 2015, 26(3):440-52

PubMed: ( click the link to review the publication )

Cell Cycle, 2015, 14(2):219-31

PubMed: 25607646 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2315-30

PubMed: 25537513 ( click the link to review the publication )

Oncotarget, 2015, 6(7):5275-91

PubMed: 25779659 ( click the link to review the publication )

Oncotarget, 2015, 6(33):34475-93

PubMed: 26439686 ( click the link to review the publication )

Nat Cell Biol, 2014, 16(6):538-49

PubMed: 24776885 ( click the link to review the publication )

Clin Cancer Res, 2014, 20(12):3211-21

PubMed: 24771642 ( click the link to review the publication )

Cancer Res, 2014, 74(20):5878-90

PubMed: 25125659 ( click the link to review the publication )

ACS Chem Biol, 2014, 9(5):1160-71

PubMed: 24568369 ( click the link to review the publication )
Antimicrob Agents Chemother, 2014, 13(5):1054-66

PubMed: 24748653 ( click the link to review the publication )

J Biol Chem, 2014, 289(38):26344-56

PubMed: 25100726 ( click the link to review the publication )

J Biol Chem, 2014, 289(18):12313-29

PubMed: 24634213 ( click the link to review the publication )

J Biol Chem, 2014, 289,14066-14074

PubMed: ( click the link to review the publication )

J Biol Chem, 2014, 289(20):14066-74

PubMed: 24706748 ( click the link to review the publication )

Cell Cycle, 2014, 13(2):303-14

PubMed: 24247149 ( click the link to review the publication )

Cell Cycle, 2014, 13(24):3867-77

PubMed: 25558830 ( click the link to review the publication )

Cell Cycle, 2014, 13(14):2248-61

PubMed: 24875404 ( click the link to review the publication )

Biosci Rep, 2014, 34(3)

PubMed: 24844881 ( click the link to review the publication )

PLoS One, 2014, 9(12):e115228

PubMed: 25542032 ( click the link to review the publication )

PLoS One, 2014, 8(10):e77053

PubMed: 24204733 ( click the link to review the publication )

Oncotarget, 2014, 5(3):667-78

PubMed: 24525428 ( click the link to review the publication )

The University of Queensland, 2014, Fawzi Faisal A. Bokhari

PubMed: ( click the link to review the publication )

Dev Cell, 2013, 25(6):555-71

PubMed: 23769972 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2013, 110(32):13026-31

PubMed: 23878225 ( click the link to review the publication )

Cancer Res, 2013, 73(22):6722-33

PubMed: 24101154 ( click the link to review the publication )

Cancer Res, 2013, 73(2):813-23

PubMed: 23144294 ( click the link to review the publication )

Cancer Res, 2013, 73(20):6310-22

PubMed: 24067506 ( click the link to review the publication )

Oncogene, 2013, 10.1038/onc.2013.518

PubMed: 24317508 ( click the link to review the publication )

Br J Cancer, 2013, 110(2):510-9

PubMed: 24327015 ( click the link to review the publication )

Gynecol Oncol, 2013, 128(3):461-9

PubMed: 23146687 ( click the link to review the publication )

J Biol Chem, 2013, 288(33):23765-75

PubMed: 23814058 ( click the link to review the publication )

J Biol Chem, 2013, 288(20):14158-69

PubMed: 23504319 ( click the link to review the publication )

Invest Ophthalmol Vis Sci, 2013, 54(13):8353-63

PubMed: 24366665 ( click the link to review the publication )
Cancer Biol Ther, 2013, 14(5):436-49

PubMed: 23377828 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77390

PubMed: 24155950 ( click the link to review the publication )

J Biomol Screen, 2013, 18(1):54-66

PubMed: 22923784 ( click the link to review the publication )

Biol Open, 2013, 2(5):479-86

PubMed: 23789096 ( click the link to review the publication )

J Biol Chem, 2012, 287(6):4376-85

PubMed: 22184120 ( click the link to review the publication )

J Biol Chem, 2012, 287(21):17088-99

PubMed: 22467873 ( click the link to review the publication )

Cell Cycle, 2012, 11(3):543-53

PubMed: 22262171 ( click the link to review the publication )

PLoS One, 2012, 7(6):e38838

PubMed: 22701722 ( click the link to review the publication )

Biotechniques, 2012, 10.2144/000113866

PubMed: ( click the link to review the publication )

Biotechniques, 2012, 53(1)

PubMed: 26307252 ( click the link to review the publication )

Nat Cell Biol, 2011, 13(10):1265-71

PubMed: 21874008 ( click the link to review the publication )

Cancer Res, 2011, 71(4):1385-95

PubMed: 21303981 ( click the link to review the publication )

Cancer Res, 2011, 71(17):5659-69

PubMed: 21693658 ( click the link to review the publication )

J Cell Biol, 2011, 193(6):1083-99

PubMed: 21646404 ( click the link to review the publication )

Oncogene, 2011, 30(46):4666-77

PubMed: 21602893 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(9):1886-95

PubMed: 21654832 ( click the link to review the publication )

产品安全说明书

PLK抑制剂选择性比较

生物活性

产品描述

特性

BI 2536是第一个有效的Plk1选择性抑制剂，抑制 Plk1的标记。

靶点

PLK1 ^[1] (Cell-free assay)	PLK2 ^[1] (Cell-free assay)	PLK3 ^[1] (Cell-free assay)
0.83 nM	3.5 nM	9.0 nM

体外研究

除了Plk1, BI 2536也抑制 Plk2 和Plk3活性，只是抑制程度低点,IC50分别为3.5 nM和9.0 nM。BI 2536比一组63种其他蛋白激酶（IC50>10 μM）选择性高1000多倍。BI 2536 按10 nM 到 100 nM剂量作用于HeLa细胞，抑制有丝分裂中心体中γ-微管蛋白招募和Apc6 磷酸化，抑制染色体臂中释放黏结蛋白, 诱导产生单极主轴，及一些依赖Plk1的其他有丝分裂过程。与作用于Plk1 RNAi效果相一致, BI 2536处理HeLa细胞，使细胞周期停在G2/M期, 随后DNA分解及凋亡，且累积断裂的PARP p85片段，这种作用存在浓度依赖性。BI 2536抑制一组32种人肿瘤细胞系生长，EC50为2-25 nM,抑制指数生长的hTERT-RPE1,人脐静脉内皮细胞 (HUVECs),和正常大鼠肾脏(NRK) 细胞的增殖，EC50为12-31 nM。^[1] BI 2536 抑制Plk1，降低甲状腺未分化癌(ATC)细胞如 CAL62, OCUT-1, SW1736, 8505C,和 ACT-1 的生长的生长和活力，EC50为1.4-5.6 nM。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
PSN1	NETTOlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnnqTWM2OD1yLkCwO\|c3KM7:TR?=	MoD5V2FPT0WU
ACN	NHjHXnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFzXNoVKSzVyPUCuNFA5PDNizszN	MknoV2FPT0WU
TE-8	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnvhTWM2OD1yLkCwPVQyKM7:TR?=	NIjEbmtUSU6JRWK=
LC-2-ad	NVXLXJZYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYLJR\|UxRTBwMEGwPVMh\|ryP	M1nrdHNCVkeHUh?=
ALL-PO	NGm3cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoP1TWM2OD1yLkCxN{DPxE1?	NUHsTpU1W0GQR1XS
EW-16	MnzSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MojZTWM2OD1yLkCxN\|M3KM7:TR?=	MVPTRW5ITVJ?
KM12	M2TzVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWntXYNwUUN3ME2wMlAyOzR6IN88US=>	NIPPdnFUSU6JRWK=
GI-1	NVHGXXFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXmySJp[UUN3ME2wMlAyOzh\|IN88US=>	M1u5XnNCVkeHUh?=
LS-411N	MmHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmDXTWM2OD1yLkCxOFA4KM7:TR?=	NUf2PJVJW0GQR1XS
ES8	NVG3epg1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTBwMEG0PVQh\|ryP	NGrObJNUSU6JRWK=
SNU-C2B	MlnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmezTWM2OD1yLkCxOVI3KM7:TR?=	NGTsfIxUSU6JRWK=
CESS	M{fVNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{O3e2lEPTB;MD6wNVYxOiEQvF2=	NXmwNmJoW0GQR1XS
697	Mnj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XuZmlEPTB;MD6wNVY3QCEQvF2=	MYXTRW5ITVJ?
NCI-H1963	Mn;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXvnS453UUN3ME2wMlAyPjd\|IN88US=>	NI[1clZUSU6JRWK=
IA-LM	NGDLSoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVLJR\|UxRTBwMEG2PFgh\|ryP	NYXIOJJOW0GQR1XS
SW954	NES5VXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3fTWmlEPTB;MD6wNVcxPSEQvF2=	MVvTRW5ITVJ?
RL95-2	M2fUWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3W0XWlEPTB;MD6wNVc{QCEQvF2=	MYTTRW5ITVJ?
LXF-289	M1P2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2T6PWlEPTB;MD6wNVc4KM7:TR?=	MVTTRW5ITVJ?
OCUB-M	Mn\ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe2coFKSzVyPUCuNFE5OjZizszN	MWfTRW5ITVJ?
RKO	M4LoRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{HaT2lEPTB;MD6wNVk5PyEQvF2=	MWDTRW5ITVJ?
LOUCY	NV[5Tm9NT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwMEKwOUDPxE1?	MmX0V2FPT0WU
NOS-1	NVXHd2hwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFrXboRKSzVyPUCuNFIxQTNizszN	MoTIV2FPT0WU
A4-Fuk	M{LLfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFLObVVKSzVyPUCuNFIzOThizszN	M{LJNXNCVkeHUh?=
A388	M1\Mbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYrJR\|UxRTBwMEKyNlch\|ryP	M3P5[XNCVkeHUh?=
TE-9	Ml\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX[0NJVrUUN3ME2wMlAzOjZzIN88US=>	M2[1TnNCVkeHUh?=
KURAMOCHI	M{Lmc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfHTWM2OD1yLkCyNlg2KM7:TR?=	NWfU[Zp2W0GQR1XS
KALS-1	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWHJR\|UxRTBwMEKzN\|gh\|ryP	NFm0WpFUSU6JRWK=
HOP-62	M4mxc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVjJR\|UxRTBwMEK0NkDPxE1?	MmnnV2FPT0WU
RPMI-8402	M3jzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVPJR\|UxRTBwMEK1NFgh\|ryP	M2i3[nNCVkeHUh?=
TE-1	M3nhXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jLZWlEPTB;MD6wNlUyOiEQvF2=	NFriU5ZUSU6JRWK=
CCRF-CEM	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTBwMEK1OFMh\|ryP	M1\rfnNCVkeHUh?=
HUTU-80	NIS4VldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGfNRZhKSzVyPUCuNFI3OjRizszN	NWTpUZVJW0GQR1XS
NCI-H1648	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlzrTWM2OD1yLkCyOlQ4KM7:TR?=	M3j5VHNCVkeHUh?=
HCE-4	M17oSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUXNUY9SUUN3ME2wMlAzPjh{IN88US=>	MkjiV2FPT0WU
ETK-1	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYXJR\|UxRTBwMEK3N\|Yh\|ryP	NVfRSmVQW0GQR1XS
TE-15	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlTITWM2OD1yLkCyO\|M5KM7:TR?=	NGTOW5pUSU6JRWK=
BE-13	M4fjRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2\3WGlEPTB;MD6wNlc1KM7:TR?=	MULTRW5ITVJ?
KE-37	M1PCUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NULtWJBVUUN3ME2wMlAzPzRzIN88US=>	M4\kcnNCVkeHUh?=
NCI-H1355	MoqxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mn7RTWM2OD1yLkCyO\|g{KM7:TR?=	NGXOZmZUSU6JRWK=
TE-11	M1TQfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWT3dJl7UUN3ME2wMlAzQDB7IN88US=>	MUDTRW5ITVJ?
BL-70	MoroS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorvTWM2OD1yLkCyPFU4KM7:TR?=	M3fzeHNCVkeHUh?=
ES6	NGSzRW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnLBTWM2OD1yLkCyPFgyKM7:TR?=	NXjNbnBnW0GQR1XS
GT3TKB	NV;LZo1KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwMEK5OVMh\|ryP	M3rGSnNCVkeHUh?=
LB647-SCLC	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX\TcG9LUUN3ME2wMlA{OTl3IN88US=>	MXvTRW5ITVJ?
NB13	MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUXJR\|UxRTBwMEOzNVYh\|ryP	M4ixUXNCVkeHUh?=
ST486	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1Ls[mlEPTB;MD6wN\|M{PyEQvF2=	Mk\kV2FPT0WU
NCI-H82	NXrJ[nN7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYXJR\|UxRTBwMEOzOFMh\|ryP	M33VbHNCVkeHUh?=
NTERA-S-cl-D1	MmLvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTBwMEOzPVkh\|ryP	MmTEV2FPT0WU
ES4	MkO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Xy[GlEPTB;MD6wN\|Q3OyEQvF2=	M4Pq[HNCVkeHUh?=
SK-NEP-1	M3jGUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWTJR\|UxRTBwMEO0PVkh\|ryP	MkTPV2FPT0WU
Becker	Mlz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFPaN5dKSzVyPUCuNFM2PTVizszN	M3\hbHNCVkeHUh?=
A101D	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVjQXVhJUUN3ME2wMlA{PzR6IN88US=>	MmS4V2FPT0WU
SK-UT-1	NV\sSWx4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXvJR\|UxRTBwMEO3O\|Qh\|ryP	NXjvV5dqW0GQR1XS
SW982	NIjTPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\1WVFKSzVyPUCuNFM4QSEQvF2=	MY\TRW5ITVJ?
TE-10	MlOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF;pRoNKSzVyPUCuNFQxPDZizszN	NU\iXIZHW0GQR1XS
OVCAR-4	NFTDO3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlPDTWM2OD1yLkC0NFU6KM7:TR?=	M2nLSnNCVkeHUh?=
KP-N-YS	M33BU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHZTWM2OD1yLkC0NFg2KM7:TR?=	NUXROHc3W0GQR1XS
BL-41	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVz0b4ZkUUN3ME2wMlA1OTJ3IN88US=>	NEPxPZhUSU6JRWK=
MZ1-PC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NICyTHZKSzVyPUCuNFQyOjdizszN	MULTRW5ITVJ?
PF-382	NEW1N3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ezdmlEPTB;MD6wOFE6QCEQvF2=	MYfTRW5ITVJ?
MOLT-13	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{T0XGlEPTB;MD6wOFI{QCEQvF2=	NFvKUZJUSU6JRWK=
HCC1599	MknMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjpTWM2OD1yLkC0NlU5KM7:TR?=	NFTiZ2tUSU6JRWK=
IST-MEL1	NV:1ZmFNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoLaTWM2OD1yLkC0OFQzKM7:TR?=	M4DLbnNCVkeHUh?=
LU-139	NEDaUo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHP6fXBKSzVyPUCuNFQ1PDJizszN	M1LlPHNCVkeHUh?=
MS-1	M3XieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlrXTWM2OD1yLkC0O\|AyKM7:TR?=	M4T0NXNCVkeHUh?=
MFH-ino	NE\MOIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r5Z2lEPTB;MD6wOVAxOyEQvF2=	NWTmNJBsW0GQR1XS
IMR-5	Ml7tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHTNd\|RKSzVyPUCuNFUxOjFizszN	NYLrSZRIW0GQR1XS
TE-5	MkHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnXNTWM2OD1yLkC1NFY{KM7:TR?=	NXrtOmdUW0GQR1XS
DJM-1	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYrhPJM3UUN3ME2wMlA2OTR{IN88US=>	M{nmbHNCVkeHUh?=
NB17	NYfnflhOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn[yTWM2OD1yLkC1NlA4KM7:TR?=	M1ewV3NCVkeHUh?=
KARPAS-45	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVf0[HNVUUN3ME2wMlA2OzV6IN88US=>	NFfaV4RUSU6JRWK=
TGBC1TKB	M{LPO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIK1eXVKSzVyPUCuNFU1ODVizszN	MmL2V2FPT0WU
ML-2	NXvRUos3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYTJR\|UxRTBwMEW0NVQh\|ryP	NIHFOoNUSU6JRWK=
no-10	NUnrXVk1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVfJR\|UxRTBwMEW0O\|Qh\|ryP	NHfKO2VUSU6JRWK=
CTV-1	NF\ZWoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVnJR\|UxRTBwMEW1NFIh\|ryP	NYr2[IhjW0GQR1XS
SJSA-1	M3HNNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIT2U4VKSzVyPUCuNFU2OiEQvF2=	MnPyV2FPT0WU
HC-1	M1THZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\0XWlEPTB;MD6wOVU6PyEQvF2=	NE\CZXFUSU6JRWK=
TE-12	Ml2xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwMEW2NVMh\|ryP	MYPTRW5ITVJ?
KY821	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWPlbXl[UUN3ME2wMlA2PjN{IN88US=>	NYf1eYN1W0GQR1XS
TALL-1	M{LkNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1HpcWlEPTB;MD6wOVcxQCEQvF2=	MnjiV2FPT0WU
DEL	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMEW3NFkh\|ryP	NHXmc5BUSU6JRWK=
TE-6	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{G1UWlEPTB;MD6wOVczOiEQvF2=	MXvTRW5ITVJ?
SK-LMS-1	M{XNNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{K2N2lEPTB;MD6wOVgxPSEQvF2=	NEf2W3dUSU6JRWK=
EW-1	MlLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEHtRXdKSzVyPUCuNFU5OzdizszN	MlLPV2FPT0WU
8-MG-BA	MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1zRWmlEPTB;MD6wOVg2OSEQvF2=	MofyV2FPT0WU
NALM-6	M2nLWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkfHTWM2OD1yLkC1PVc{KM7:TR?=	NF[0RmhUSU6JRWK=
LB771-HNC	M3rS[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mm[1TWM2OD1yLkC1PVc6KM7:TR?=	M3\Wb3NCVkeHUh?=
HT-144	NID0dWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGLLT5hKSzVyPUCuNFYyOyEQvF2=	MnfXV2FPT0WU
KM-H2	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jNW2lEPTB;MD6wOlIzOSEQvF2=	MUfTRW5ITVJ?
SF268	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXQTWM2OD1yLkC2Nlg3KM7:TR?=	NUTM[4dvW0GQR1XS
RS4-11	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkf4TWM2OD1yLkC2N\|A1KM7:TR?=	MYHTRW5ITVJ?
MHH-PREB-1	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXP4V5VXUUN3ME2wMlA3OzF7IN88US=>	MkjNV2FPT0WU
ATN-1	MnTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXXJR\|UxRTBwME[zOFUh\|ryP	NWDaXGdZW0GQR1XS
BB30-HNC	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXnqcoZmUUN3ME2wMlA3PDN4IN88US=>	MYjTRW5ITVJ?
CPC-N	MkC4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFnPPXlKSzVyPUCuNFY2OjRizszN	MVzTRW5ITVJ?
NB1	M3r0NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\EOmlEPTB;MD6wOlYyOyEQvF2=	NEnJe3BUSU6JRWK=
KS-1	NIHm[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIHkNmhKSzVyPUCuNFY4PDhizszN	NIG3cJFUSU6JRWK=
RXF393	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mon1TWM2OD1yLkC2O\|Y1KM7:TR?=	NI\wPFlUSU6JRWK=
IST-SL2	M1foXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTBwMEewNFQh\|ryP	NFnEXZVUSU6JRWK=
GI-ME-N	Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrvfY5KSzVyPUCuNFczQDZizszN	MnXHV2FPT0WU
VA-ES-BJ	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH;GUHVKSzVyPUCuNFc1PzVizszN	M2e4fXNCVkeHUh?=
NCI-H1581	NEHPVFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn7yTWM2OD1yLkC3OFc5KM7:TR?=	NHvZbJVUSU6JRWK=
U-266	NHjvXlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwMEe0PVch\|ryP	MYLTRW5ITVJ?
DMS-114	MoTWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUPJR\|UxRTBwMEe1Nlgh\|ryP	NEfPSnBUSU6JRWK=
NCI-H187	NFnBTFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\iTWM2OD1yLkC3O\|I3KM7:TR?=	M3fkRnNCVkeHUh?=
SW962	NXnS[nFkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEW4WG1KSzVyPUCuNFc5OzlizszN	Mni2V2FPT0WU
MONO-MAC-6	MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mm\WTWM2OD1yLkC3PVg3KM7:TR?=	MljuV2FPT0WU
MOLT-16	M1HlUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGnTeHJKSzVyPUCuNFgyOjFizszN	MkG1V2FPT0WU
KNS-42	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHX2PVJKSzVyPUCuNFgyPjFizszN	M{L6OHNCVkeHUh?=
CMK	Ml;CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV\oOHdwUUN3ME2wMlA5OjJ3IN88US=>	M1TnTHNCVkeHUh?=
Ramos-2G6-4C10	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{TzVGlEPTB;MD6wPFIzPSEQvF2=	NWrGV21jW0GQR1XS
Daudi	NHXr[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTBwMEiyOVYh\|ryP	Ml\3V2FPT0WU
NCI-H510A	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWKyTG9lUUN3ME2wMlA5OzN4IN88US=>	NGTTeoJUSU6JRWK=
LB831-BLC	M1LGfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFTjV3hKSzVyPUCuNFg2PjFizszN	NXK5N\|R[W0GQR1XS
HEL	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGPRSnVKSzVyPUCuNFg3PjhizszN	NXzjcoJyW0GQR1XS
LU-134-A	M3\3cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWHJR\|UxRTBwMEi3NFgh\|ryP	NU\0XnZ{W0GQR1XS
NCI-H1694	M4DyO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHXuV2tKSzVyPUCuNFg4PDRizszN	MVLTRW5ITVJ?
KGN	M3X4Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M37JO2lEPTB;MD6wPFc2QSEQvF2=	NUfueItbW0GQR1XS
A253	Mo\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIDMdVRKSzVyPUCuNFg5OjJizszN	MWXTRW5ITVJ?
DG-75	Mn7iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|UxRTBwMEi5NlIh\|ryP	M1GwXHNCVkeHUh?=
MOLT-4	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MXXJR\|UxRTBwMEi5PFMh\|ryP	MkfrV2FPT0WU
NCI-SNU-5	M3P5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmfDTWM2OD1yLkC5NlU5KM7:TR?=	MnHPV2FPT0WU
ONS-76	NVS5fFIyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXfMZXVzUUN3ME2wMlA6Ojd4IN88US=>	NGXWUHZUSU6JRWK=
NCI-H446	MnzpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFLuc3NKSzVyPUCuNFk1PjJizszN	NY\BPWNkW0GQR1XS
COR-L279	MoXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTPTWM2OD1yLkC5OVU3KM7:TR?=	MmPoV2FPT0WU
Calu-6	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NE\W[oNKSzVyPUCuNFk2QThizszN	MVvTRW5ITVJ?
BC-3	NILQdYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NESwN41KSzVyPUCuNFk3PjJizszN	M3HS[HNCVkeHUh?=
NCI-H2126	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUXr[5V7UUN3ME2wMlA6PzlzIN88US=>	MXvTRW5ITVJ?
NCI-H1882	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mk[0TWM2OD1yLkC5PFA6KM7:TR?=	MUfTRW5ITVJ?
BB65-RCC	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUfJR\|UxRTBwMUCyPVQh\|ryP	NVjjUG1GW0GQR1XS
DU-4475	NWLZNZdIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXzJR\|UxRTBwMUC0NFch\|ryP	NHW4fnpUSU6JRWK=
NCI-H526	Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVrWZ3FVUUN3ME2wMlExPDRizszN	MVXTRW5ITVJ?
NEC8	M2TTOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnPITWM2OD1yLkGwOVI2KM7:TR?=	Ml2xV2FPT0WU
NCI-H1304	M1\jemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2C3T2lEPTB;MD6xNFU6PCEQvF2=	MXvTRW5ITVJ?
L-540	Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MknMTWM2OD1yLkGwO\|A5KM7:TR?=	MW\TRW5ITVJ?
NCI-SNU-16	NV\JPY9YT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTBwMUC3OFIh\|ryP	M3i0VnNCVkeHUh?=
HD-MY-Z	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fBXGlEPTB;MD6xNFg2PiEQvF2=	NGTsfHVUSU6JRWK=
K-562	MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPEfppKSzVyPUCuNVA5PThizszN	NVXyV\|lHW0GQR1XS
JAR	NFHlbYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NInOdppKSzVyPUCuNVA6OjVizszN	M1T3PXNCVkeHUh?=
MZ2-MEL	NHmxPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXTJR\|UxRTBwMUGwOUDPxE1?	NYmzRnFKW0GQR1XS
L-363	Mn\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUHJR\|UxRTBwMUGwO\|kh\|ryP	NX;RNmtUW0GQR1XS
BV-173	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXuzSWZLUUN3ME2wMlEyOjR\|IN88US=>	MV3TRW5ITVJ?
NCI-H524	NVLMfVZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwMUGyO\|Qh\|ryP	MULTRW5ITVJ?
EoL-1-cell	M2XSRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4G5V2lEPTB;MD6xNVY4OiEQvF2=	Mk\YV2FPT0WU
K052	MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH6wWY1KSzVyPUCuNVE4OTJizszN	NEPzUIJUSU6JRWK=
TK10	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH\YWndKSzVyPUCuNVE4OjhizszN	MoTIV2FPT0WU
KU812	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHrjO2RKSzVyPUCuNVIxPDRizszN	NIThNG5USU6JRWK=
RPMI-8226	NFHnVpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MoHkTWM2OD1yLkGyNFUzKM7:TR?=	NVLVTVM6W0GQR1XS
MZ7-mel	NXSyZZRPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYOxdm5yUUN3ME2wMlEzOjN5IN88US=>	MVLTRW5ITVJ?
SK-PN-DW	MoPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPaTWM2OD1yLkGyNlg4KM7:TR?=	MVvTRW5ITVJ?
SR	NV;GPHZMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUjGeHd5UUN3ME2wMlEzPDRzIN88US=>	NWPXXI9DW0GQR1XS
RPMI-6666	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1fhdGlEPTB;MD6xNlc1OyEQvF2=	MVzTRW5ITVJ?
no-11	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1HmVmlEPTB;MD6xNlg3QSEQvF2=	NF7zVm5USU6JRWK=
EW-3	NXrnSnpyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3rjOWlEPTB;MD6xNlg6OyEQvF2=	MofYV2FPT0WU
LAMA-84	MkHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGrIOVdKSzVyPUCuNVMyQDdizszN	NGPXeXNUSU6JRWK=
HT	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlLpTWM2OD1yLkGzOVc1KM7:TR?=	NIPibIxUSU6JRWK=
KP-N-RT-BM-1	NWjBUXMzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NE\jSpJKSzVyPUCuNVM3OTJizszN	NEPLdFNUSU6JRWK=
NCI-H747	M125V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13uVGlEPTB;MD6xN\|ch\|ryP	NX\zSYNlW0GQR1XS
NCCIT	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYHJR\|UxRTBwMUO5N\|kh\|ryP	NF\XU2NUSU6JRWK=
MLMA	MofES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFfDdmtKSzVyPUCuNVQyPjdizszN	NWjyXYtJW0GQR1XS
LP-1	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NISwOWNKSzVyPUCuNVQzPCEQvF2=	NV\3S4dHW0GQR1XS
CAL-148	Mmn3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTBwMUS0PFMh\|ryP	MYDTRW5ITVJ?
GB-1	Mn\RS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX24UHM{UUN3ME2wMlE1PTJ4IN88US=>	Mk\rV2FPT0WU
COR-L88	MmSxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4HjXGlEPTB;MD6xOFgxOiEQvF2=	NHPNWFRUSU6JRWK=
NKM-1	NGPL[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NITuNlNKSzVyPUCuNVQ6ODZizszN	M3[4TnNCVkeHUh?=
NB5	NUnhSnprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIfMRpZKSzVyPUCuNVU1PjJizszN	NVW3W\|FwW0GQR1XS
SH-4	NGTFNY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIj5cm9KSzVyPUCuNVU1PjZizszN	NYjL[m5UW0GQR1XS
EM-2	MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTBwMUW0Olch\|ryP	NVfV[m06W0GQR1XS
TGBC24TKB	Mk\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUfaVFVmUUN3ME2wMlE2PjV7IN88US=>	NUfkW4V2W0GQR1XS
SCLC-21H	M{Sz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M13vd2lEPTB;MD6xOVcxOiEQvF2=	NUPidlBuW0GQR1XS
COLO-684	M1zHTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rIeGlEPTB;MD6xOVczOSEQvF2=	Mn[yV2FPT0WU
KINGS-1	NFLaV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXjMe\|B4UUN3ME2wMlE2QTFizszN	NEHhR3NUSU6JRWK=
LS-123	M3mxNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljRTWM2OD1yLkG1PVE4KM7:TR?=	NH7Ud5RUSU6JRWK=
MC116	MljuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3;jRmlEPTB;MD6xOlE2QCEQvF2=	MUPTRW5ITVJ?
SU-DHL-1	NIrNeXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYDJR\|UxRTBwMU[yNFYh\|ryP	MYDTRW5ITVJ?
NCI-H64	NGXCb21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{LLcmlEPTB;MD6xOlM1PyEQvF2=	MUjTRW5ITVJ?
HCE-T	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2\ReGlEPTB;MD6xOlUxPCEQvF2=	M2fLeHNCVkeHUh?=
LOXIMVI	NVTHVmxZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGqxdVlKSzVyPUCuNVY6PDlizszN	NWnsNXNVW0GQR1XS
ARH-77	M4r5S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPKOGpKSzVyPUCuNVc{PzlizszN	M{SzfXNCVkeHUh?=
DOHH-2	MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlrWTWM2OD1yLkG3OlczKM7:TR?=	NWK4bYgxW0GQR1XS
COLO-320-HSR	MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTBwMUixOVQh\|ryP	M2HYVXNCVkeHUh?=
NB6	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIPFd4ZKSzVyPUCuNVg2PjZizszN	NUiyeFNPW0GQR1XS
L-428	NFzZVWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2rrNGlEPTB;MD6xPFgyOyEQvF2=	M2\wOnNCVkeHUh?=
SNB75	NXzORXlJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1f1bWlEPTB;MD6xPFgzPCEQvF2=	M3W1b3NCVkeHUh?=
NCI-H2141	NHrHXFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEHmeZFKSzVyPUCuNVkxOTFizszN	M3zkd3NCVkeHUh?=
KARPAS-299	MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1v0OGlEPTB;MD6xPVI1OSEQvF2=	M4\QdHNCVkeHUh?=
LC4-1	NGTDfmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ThUGlEPTB;MD6xPVUxOiEQvF2=	NHz0fIpUSU6JRWK=
UACC-257	NID2[ZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1ezSGlEPTB;MD6xPVk1PyEQvF2=	NIf5V3ZUSU6JRWK=
EVSA-T	M4niPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHS4e\|lKSzVyPUCuNlA{OTJizszN	Ml3IV2FPT0WU
JiyoyeP-2003	NYfDRZpkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoraTWM2OD1yLkKwOFc4KM7:TR?=	NXy3WlI3W0GQR1XS
NCI-H720	NY\GOZJYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYDJR\|UxRTBwMkC1NlUh\|ryP	MYDTRW5ITVJ?
GAK	NHfHdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTBwMkGxPFkh\|ryP	M3jhXHNCVkeHUh?=
HH	NYnaNIh5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkftTWM2OD1yLkKxOFA2KM7:TR?=	M33xNHNCVkeHUh?=
NCI-H1436	NVnFOlBwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NIjnfFVKSzVyPUCuNlE1PjRizszN	MlnvV2FPT0WU
GR-ST	MnPVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LQT2lEPTB;MD6yNVQ5QCEQvF2=	NVrreWxIW0GQR1XS
BC-1	Mk\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4fRdGlEPTB;MD6yNlYyPiEQvF2=	NWHzO2RUW0GQR1XS
SIG-M5	NGfOTpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Ml76TWM2OD1yLkKyO\|I4KM7:TR?=	M3[4eXNCVkeHUh?=
NCI-H345	NIfWdnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3XnUWlEPTB;MD6yN\|gxPSEQvF2=	MXrTRW5ITVJ?
OPM-2	M1HUbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnO5TWM2OD1yLkKzPFgzKM7:TR?=	M4frbHNCVkeHUh?=
LB1047-RCC	NHrGXWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlvrTWM2OD1yLkK0OFEh\|ryP	NV\rS5BiW0GQR1XS
CTB-1	NXfEPHlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojBTWM2OD1yLkK0OFk{KM7:TR?=	NGjWUlNUSU6JRWK=
A3-KAW	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NYPtco9xUUN3ME2wMlI2OzRzIN88US=>	NUHu[GppW0GQR1XS
SF126	MmTkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWfJR\|UxRTBwMkWzPFMh\|ryP	Mn;WV2FPT0WU
KARPAS-422	NGrpZVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfjUXpKSzVyPUCuNlU1OzVizszN	M2\CZnNCVkeHUh?=
MEG-01	NXy2V4lXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYrLVXdWUUN3ME2wMlI2Pjd\|IN88US=>	NWrVPJpnW0GQR1XS
NCI-H209	NF;LT5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmmxTWM2OD1yLkK2N\|c1KM7:TR?=	NIXBPFlUSU6JRWK=
SBC-1	NYL3W4FGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnL6TWM2OD1yLkK2OUDPxE1?	M360e3NCVkeHUh?=
K5	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWrJR\|UxRTBwMk[5PFQh\|ryP	MWrTRW5ITVJ?
QIMR-WIL	M1TTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVnJR\|UxRTBwMkexOVUh\|ryP	NUjYSVNQW0GQR1XS
NMC-G1	NXPvcJJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGH4RmtKSzVyPUCuNlgzOTdizszN	M2nZWXNCVkeHUh?=
IST-MES1	M1jkRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUWzW5NOUUN3ME2wMlI6OjN6IN88US=>	M1XqVnNCVkeHUh?=
SW684	Mn\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXvJR\|UxRTBwM{CwOFch\|ryP	MoXGV2FPT0WU
MV-4-11	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfvbmpKSzVyPUCuN\|A4QDhizszN	M3\XXnNCVkeHUh?=
LAN-6	NEG2NJJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIn2dJZKSzVyPUCuN\|E2PzJizszN	NFmzWYlUSU6JRWK=
RH-1	MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3G5VGlEPTB;MD6zNVg4OSEQvF2=	NIrzb49USU6JRWK=
CP66-MEL	MlvNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYDmWHhFUUN3ME2wMlMyQDd6IN88US=>	MVHTRW5ITVJ?
EC-GI-10	NIT2NHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUWycnRzUUN3ME2wMlMzQTh5IN88US=>	NV\Tdm4yW0GQR1XS
GDM-1	MkLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M32wUGlEPTB;MD6zN\|A2QSEQvF2=	MlvWV2FPT0WU
IST-SL1	NYe5em5lT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXJTWM2OD1yLkO0PVE1KM7:TR?=	NYDqc5RWW0GQR1XS
KMOE-2	Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWW2TFBDUUN3ME2wMlM2OTd3IN88US=>	Mn3jV2FPT0WU
OS-RC-2	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFi1OmVKSzVyPUCuN\|U2PDRizszN	MULTRW5ITVJ?
HDLM-2	M4TNeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1zrWWlEPTB;MD6zO\|gyPCEQvF2=	M{OyVnNCVkeHUh?=
DSH1	M1XYZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2HwO2lEPTB;MD6zPFY{OSEQvF2=	MnjyV2FPT0WU
LS-1034	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jDNWlEPTB;MD6zPFk2PCEQvF2=	NWfoZY1OW0GQR1XS
LB373-MEL-D	NX\YOHprT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mlq4TWM2OD1yLkO5NVk4KM7:TR?=	M3y3[nNCVkeHUh?=
GOTO	MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWnIfmVWUUN3ME2wMlQzOTF6IN88US=>	NYrjb\|E6W0GQR1XS
MRK-nu-1	M4j5dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIjCXnlKSzVyPUCuOFIzODVizszN	M1;aRXNCVkeHUh?=
SK-MM-2	NXHZOpVyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYfzO4tHUUN3ME2wMlQ{PDR{IN88US=>	M1LpbXNCVkeHUh?=
BOKU	Mlf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVvJR\|UxRTBwNEO3PVIh\|ryP	MYjTRW5ITVJ?
NOMO-1	NXP4eHVJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{fu[GlEPTB;MD60N\|g3KM7:TR?=	MmK1V2FPT0WU
J-RT3-T3-5	MkXDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEe3VYJKSzVyPUCuOFQ5PzhizszN	NGDpW4FUSU6JRWK=
COLO-668	NUTheJF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVLaZpI4UUN3ME2wMlQ2PjZ6IN88US=>	NX\vZnA3W0GQR1XS
SF539	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy5W5FKSzVyPUCuOFg3QDRizszN	Mn;vV2FPT0WU
LB2518-MEL	NHzBeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWPJR\|UxRTBwNEm3NFMh\|ryP	MWXTRW5ITVJ?
TE-441-T	NXzHRXZlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYfJR\|UxRTBwNUCxNkDPxE1?	MVrTRW5ITVJ?
MDA-MB-134-VI	Mon3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX\JR\|UxRTBwNUC5NlEh\|ryP	MXjTRW5ITVJ?
SCC-3	NV7tdZFXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYrJR\|UxRTBwNUG4O\|Mh\|ryP	MUXTRW5ITVJ?
KLE	NEDWO5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXfJR\|UxRTBwNUKxO\|Eh\|ryP	NWPXcWRqW0GQR1XS
LB2241-RCC	M{fkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEjuZ4RKSzVyPUCuOVI2OjVizszN	M4S5bXNCVkeHUh?=
NCI-H1417	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmnTTWM2OD1yLkWzOFM2KM7:TR?=	Mm\CV2FPT0WU
NCI-H2081	M3;SZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVe4UZQ4UUN3ME2wMlU5PjFzIN88US=>	NELPd3lUSU6JRWK=
NCI-H1522	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mo[3TWM2OD1yLkW5N\|g{KM7:TR?=	MUfTRW5ITVJ?
NCI-H889	MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDFZVR3UUN3ME2wMlU6QDR2IN88US=>	MYXTRW5ITVJ?
CGTH-W-1	NF[3RlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYfJR49IUUN3ME2wMlYxPzV3IN88US=>	NYH4THJIW0GQR1XS
EB-3	MlfsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j6OGlEPTB;MD62NVE2OyEQvF2=	MkTuV2FPT0WU
D-336MG	M2\TSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXnJR\|UxRTBwNkG3PVEh\|ryP	MljoV2FPT0WU
LC-1F	NXjQ[GtCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFjTW2xKSzVyPUCuOlI2QTJizszN	NGPXV\|hUSU6JRWK=
MHH-NB-11	MnPBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Ml:3TWM2OD1yLk[zPFAyKM7:TR?=	NWXiWXBTW0GQR1XS
SK-N-FI	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{izRmlEPTB;MD62N\|kyKM7:TR?=	NFXWZY5USU6JRWK=
NCI-H69	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUTJR\|UxRTBwNkS4O\|kh\|ryP	MXPTRW5ITVJ?
SCH	M4f4cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTBwNk[wNlMh\|ryP	NYfJPI95W0GQR1XS
LS-513	M4jjcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfRNHpKSzVyPUCuOlczPTlizszN	NGfFSVVUSU6JRWK=
CP67-MEL	M1S2[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGDLfm9KSzVyPUCuOlc2QTZizszN	M4HVW3NCVkeHUh?=
GCIY	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4jmZ2lEPTB;MD63NFM3OyEQvF2=	NVS4UJR7W0GQR1XS
SHP-77	NVTYd2k4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTBwN{C3N\|Qh\|ryP	NHv3PHVUSU6JRWK=
EHEB	M4XZ[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXq3eWZEUUN3ME2wMlcyQDV2IN88US=>	MXjTRW5ITVJ?
D-247MG	MofKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEXz[JNKSzVyPUCuO\|MzOzJizszN	M{\FVnNCVkeHUh?=
Raji	M{HJO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWK5fXVIUUN3ME2wMlc1QTh7IN88US=>	MoXQV2FPT0WU
MPP-89	NGK0[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXIV2pKSzVyPUCuO\|U6PzhizszN	NFvLTZJUSU6JRWK=
EKVX	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmD6TWM2OD1yLke5NFc{KM7:TR?=	NXroU3ZqW0GQR1XS
HCC2218	NULzfYxrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3vyWmlEPTB;MD63PVE{OSEQvF2=	NHTiUopUSU6JRWK=
KNS-81-FD	NI\LNJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWLIepBmUUN3ME2wMlgyODFzIN88US=>	MVLTRW5ITVJ?
HCC2157	MoPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWC2bm9RUUN3ME2wMlg1QTVzIN88US=>	NIK5TWVUSU6JRWK=
BT-474	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUHxc\|dFUUN3ME2wMlg5QDV2IN88US=>	M4[5enNCVkeHUh?=
NCI-H748	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEfKU\|ZKSzVyPUCuPVEzKM7:TR?=	MlvVV2FPT0WU
EW-24	NVfjOWU2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{LIU2lEPTB;MD65NlAxOiEQvF2=	MlqxV2FPT0WU
D-263MG	NVTaTJA6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGjnZmpKSzVyPUCuPVQ2OTJizszN	MlXPV2FPT0WU
OMC-1	M{jmdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvFdlZKSzVyPUCuPVY{PzNizszN	MnixV2FPT0WU
NCI-H2196	MorNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVLJR\|UxRTBwOUe3O\|ch\|ryP	NXuwNJp{W0GQR1XS
HAL-01	M3rEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHuyVYRKSzVyPUCuPVk5PzJizszN	M2jLOHNCVkeHUh?=
NCI-H2107	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWjJR\|UxRTFwMEG4OVQh\|ryP	NU[xfodlW0GQR1XS
LB996-RCC	NVfvfmFZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1TVTWlEPTB;MT6wPFA2OSEQvF2=	M1TDXHNCVkeHUh?=
NCI-H1395	MlrWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEjiVYpKSzVyPUGuNVA3PyEQvF2=	MVPTRW5ITVJ?
CHP-126	NU\LV2lvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4fjUGlEPTB;MT6xOlE6QSEQvF2=	NHv1fWtUSU6JRWK=
NB69	NUHLdnFqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzRN4YzUUN3ME2xMlI3OTR6IN88US=>	MlrKV2FPT0WU
CAS-1	NXfUN2VwT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlnPTWM2OD1zLkO0NlMyKM7:TR?=	M2rY[nNCVkeHUh?=
JVM-3	NHPGfGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWjJR\|UxRTFwNEe4OVUh\|ryP	M{XwZnNCVkeHUh?=
DMS-153	NGPTVpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF;kNZpKSzVyPUGuOVc3PzRizszN	NUj2d3ZQW0GQR1XS
SK-MEL-2	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGm0[olKSzVyPUGuO\|E4QDlizszN	MUnTRW5ITVJ?
NCI-H1155	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{nRZmlEPTB;MT63N\|Y4PiEQvF2=	M3P0UHNCVkeHUh?=
NCI-H1092	MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3jDdGlEPTB;MT63OlE5OiEQvF2=	NFPL[YpUSU6JRWK=
LU-165	NHfrVVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWPB[GZDUUN3ME2xMlg3PDd4IN88US=>	MX\TRW5ITVJ?
HL-60	MmrJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXnpRVB5UUN3ME2xMlk6QTB6IN88US=>	Mnu3V2FPT0WU
REH	NHfmbINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTJwMEC1PFIh\|ryP	Mn3qV2FPT0WU
JVM-2	M{X3RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlW1TWM2OD1{LkC2NVM2KM7:TR?=	M1TqTXNCVkeHUh?=
MN-60	NX6xdYRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;BXHNzUUN3ME2yMlE4OzB6IN88US=>	NWLPe2JsW0GQR1XS
SCC-15	M1u4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoHRTWM2OD1{LkKwNlch\|ryP	NYX5UmZFW0GQR1XS
SNU-C1	NGLLdJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mle1TWM2OD1{LkKxN\|Q{KM7:TR?=	NWK1[4h2W0GQR1XS
SK-MEL-1	NVzIcW9WT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX;JR\|UxRTJwM{KwOFch\|ryP	NUDJdlU6W0GQR1XS
TGW	MoHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWDJR\|UxRTJwM{WwNlch\|ryP	MUnTRW5ITVJ?
CA46	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NITacHRKSzVyPUKuO\|U6PjdizszN	MVTTRW5ITVJ?
NCI-H23	NWTI[llbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV\hRodbUUN3ME2yMlgxPzlzIN88US=>	NWjwUXR6W0GQR1XS
MMAC-SF	NVfTdXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfGR3lKSzVyPUKuPFY3OjhizszN	MXzTRW5ITVJ?
NCI-H2171	M{TwdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlXGTWM2OD1\|LkCzOFQ5KM7:TR?=	NYLXWG96W0GQR1XS
A704	MlP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{j1UGlEPTB;Mz6xOFE6PCEQvF2=	M1n3XXNCVkeHUh?=
DB	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MljhTWM2OD1\|LkK1OVc3KM7:TR?=	M13YU3NCVkeHUh?=
NCI-H719	NHSyNFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUHlNYJlUUN3ME2zMlMxOzh2IN88US=>	M{D4VnNCVkeHUh?=
MC-CAR	M{e5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYjJR\|UxRTNwNUS4NVch\|ryP	MmLnV2FPT0WU
SIMA	M3jQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4fKcWlEPTB;Mz61PFQyPiEQvF2=	NWLSOIpXW0GQR1XS
SW872	M3TJeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1rQRWlEPTB;Mz63PFExOSEQvF2=	NI\DXG1USU6JRWK=
HCC1187	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mkn1TWM2OD1\|Lke4N\|E2KM7:TR?=	MVzTRW5ITVJ?
EW-13	NELQ[YpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NV7xdll2UUN3ME2zMlg{PDF5IN88US=>	MVzTRW5ITVJ?
NCI-SNU-1	MlrwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYPUcIF2UUN3ME20MlIyQTl7IN88US=>	NFnUfGdUSU6JRWK=
NCI-H226	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWfJR\|UxRTRwM{O2NFYh\|ryP	NHH2WWlUSU6JRWK=
RPMI-8866	MofPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmLuTWM2OD12LkO2NFI6KM7:TR?=	M17hW3NCVkeHUh?=
OCI-AML2	NUDEWpg{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTxWoFqUUN3ME20MlU2OjNizszN	Mmn5V2FPT0WU
LU-65	NEXNPJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEKy[lJKSzVyPUSuPVMxOzNizszN	NXrONJBzW0GQR1XS
SK-N-DZ	NX3KXlhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX6ycoRHUUN3ME21MlY{PDZ3IN88US=>	M{ntbnNCVkeHUh?=
NB14	MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4Toc2lEPTB;NT65O\|E{PSEQvF2=	NWXs[HNZW0GQR1XS
COLO-829	NX\mdm5KT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MojLTWM2OD14LkOzN\|U6KM7:TR?=	M1zUR3NCVkeHUh?=
MHH-CALL-2	NGXlflVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2jDVmlEPTB;Nj61NVUxQCEQvF2=	Ml:wV2FPT0WU
NCI-H1770	M4\tSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mnn0TWM2OD14Lk[2PVA1KM7:TR?=	Mn\xV2FPT0WU
ECC4	MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MorOTWM2OD14LkiyNVc6KM7:TR?=	M1TmV3NCVkeHUh?=
A498	NYfkUoFrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGKz[2VKSzVyPU[uPFcyQTJizszN	M3XCOXNCVkeHUh?=
DMS-79	M1v2NGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWTwWpRUUUN3ME23MlA1PTF{IN88US=>	M{fOOHNCVkeHUh?=
P30-OHK	NX6wOJFQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MljlTWM2OD15LkKxPVA3KM7:TR?=	NEfKOpZUSU6JRWK=
D-502MG	NXK1cVd1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVj3UIdOUUN3ME23Mlk5OzZizszN	NYPMdW9xW0GQR1XS
RCC10RGB	Mk\aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTtNJNGUUN3ME24MlA3OjhizszN	NInoZmFUSU6JRWK=
U-698-M	M2LySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmXaTWM2OD16LkK5NlI3KM7:TR?=	NFvZ[3lUSU6JRWK=
BB49-HNC	NGfI[WdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYXJR\|UxRTlwNEKyOlUh\|ryP	NGGyVHpUSU6JRWK=
ES1	NHLRXFhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFPsTWRKSzVyPUmuOlg6PTZizszN	MlK2V2FPT0WU
MFM-223	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTFyLkm5Nlch\|ryP	NUXGcZpnW0GQR1XS
C2BBe1	NXzhbIlxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MmfhTWM2OD1zMT6zOVI{KM7:TR?=	M4nsTHNCVkeHUh?=
EB2	Mn7yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHLNXVBKSzVyPUGyMlY5QDFizszN	NGfXTllUSU6JRWK=
C8166	NVXpUphbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV:1OGdRUUN3ME2xN{45OzB\|IN88US=>	NUnrOI04W0GQR1XS
ES3	MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{XqOmlEPTB;MUOuPVk4PyEQvF2=	MoXaV2FPT0WU
NCI-H1650	NXrZVlJvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjhTWM2OD1zNj6zO\|Y2KM7:TR?=	M1HpTnNCVkeHUh?=
Mo-T	M{LvVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Ml;oTWM2OD1zNz60NFI6KM7:TR?=	M4HmdHNCVkeHUh?=
NB7	NGOzVYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVHmVXNRUUN3ME2xO{44PDZ5IN88US=>	NXS5RmFXW0GQR1XS
ES7	NXz6dZpET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU[5TJdoUUN3ME2xPU42PTB5IN88US=>	NUi5dmp{W0GQR1XS
ES5	NVLUZWVIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGOxOHZKSzVyPUKxMlc3PzFizszN	M2r4e3NCVkeHUh?=
MSTO-211H	MnLFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NIPhRpBKSzVyPUKxMlg5PThizszN	M3;mbHNCVkeHUh?=
U-87-MG	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NEHDPZNKSzVyPUK1MlE6PjZizszN	MoHoV2FPT0WU
THP-1	NXzOTYhYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUjJR\|UxRTJ7LkeyNFEh\|ryP	NE\OUWVUSU6JRWK=
NB10	MmXZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NHzqPWtKSzVyPUOwMlI3QTRizszN	NIPG[4FUSU6JRWK=
NH-12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXL1WIlXUUN3ME2zN{4zODF5IN88US=>	NYDZXZVkW0GQR1XS
COLO-824	NYDS[4RzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NI\PT2VKSzVyPUO0MlExODZizszN	NVrhfG13W0GQR1XS
SKM-1	NVjGeVFpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NX;MT254UUN3ME2zO{45PDJ{IN88US=>	MYHTRW5ITVJ?
NCI-H1838	M{mwbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGTISllKSzVyPUO4MlM4QTdizszN	NXHEW2s2W0GQR1XS
RL	MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml\lTWM2OD1\|OT6yOFc4KM7:TR?=	M2m2PHNCVkeHUh?=
COLO-800	NEHtcpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3r0UmlEPTB;NECuNFc4OyEQvF2=	MWTTRW5ITVJ?
KG-1	NWHzZ2VkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1X2WmlEPTB;NECuPFk2PSEQvF2=	M1HEWHNCVkeHUh?=
TUR	NVH1TnpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2j3cWlEPTB;NEGuOlM6QSEQvF2=	NHu2bFRUSU6JRWK=
LNCaP-Clone-FGC	NIDQTIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFXSWnhKSzVyPUSxMlkxOTdizszN	MYHTRW5ITVJ?
NCI-H322M	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIDTbINKSzVyPUSyMlU6QDRizszN	MVXTRW5ITVJ?
LNCaP	NHfs[pdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3SyR2lEPTB;OUGuN{BvVQ>?	NGjUTm0zPTVyNUG3OC=>
C4-2	M3PieWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1:wS2lEPTB;ODDuUS=>	NWLoc\|U1OjV3MEWxO\|Q>
JURKAT	M4n3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MXeyOEBp		MkjxTWM2OD12MU[uOlYhdk1?	MlLKNlQ2OTl7OUW=
MOLT-4	NUXId5d6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NWfEZWxTOjRiaB?=		M13IOWlEPTB;Mki1N{42KG6P	NUXCfFlwOjR3MUm5PVU>
REH	M1LudWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MX2yOEBp		MnzvTWM2OD1{OEeuOlghdk1?	M1TCVVI1PTF7OUm1
NALM-6	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M1PGb\|I1KGh?		MXnJR\|UxRTN2M{OwJI5O	MmrtNlQ2OTl7OUW=
RS 4;11	MkTLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M{\XfFI1KGh?		MWjJR\|UxRTVzOT6wOUBvVQ>?	NUXIVo5vOjR3MUm5PVU>
697	NYDOZXZpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MXqyOEBp		MUfJR\|UxRTJzMEeuNUBvVQ>?	MlfJNlQ2OTl7OUW=
SIL-ALL	MmXLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NGDm[XEzPCCq		NY\UUYhkUUN3ME2xPVkvPzdibl2=	NX72dY9QOjR3MUm5PVU>
CEM	M{PPcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFrCe24zPCCq		NGrIOFRKSzVyPUWyMlE5KG6P	MmfQNlQ2OTl7OUW=
P12	MnzLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MWOyOEBp		MlzFTWM2OD1\|OT6yO{BvVQ>?	MkP5NlQ2OTl7OUW=
NALM-16	NFTOPHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MUOyOEBp		MWnJR\|UxRTl4LkK4JI5O	NFLQcGczPDVzOUm5OS=>
JURKAT	M4PnTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NWGxRVJJPDhiaB?=		MoC5TWM2OD1zND64OEBvVQ>?	M17FTlI1PTF7OUm1
MOLT-4	MmqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1;ublQ5KGh?		MWHJR\|UxRTJ4Lk[gcm0>	MXmyOFUyQTl7NR?=
REH	NV76eZJ[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NGHNOnk1QCCq		NXrwd5M{UUN3ME20OE44OSCwTR?=	MVqyOFUyQTl7NR?=
NALM-6	NYHJW\|JDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlTBOFghcA>?		NEC2VJdKSzVyPUKzMlI3KG6P	M{DWOVI1PTF7OUm1
RS 4;11	Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXe5VHNKPDhiaB?=		M{izdmlEPTB;MU[0MlI5KG6P	NWPLdYV2OjR3MUm5PVU>
697	NUTaSFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmT6OFghcA>?		NHj4UJRKSzVyPUOwOU4{KG6P	MUWyOFUyQTl7NR?=
SIL-ALL	NGXjR2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NICwbFA1QCCq		M{fMR2lEPTB;N{SuOlIhdk1?	MlS5NlQ2OTl7OUW=
CEM	NVvOc4dET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFjhXlc1QCCq		MmjUTWM2OD1{ND61OUBvVQ>?	M{XKXlI1PTF7OUm1
P12	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWHw[mxSPDhiaB?=		MmrKTWM2OD1zOD60OkBvVQ>?	NHHNTGczPDVzOUm5OS=>
NALM-16	NIHLRmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mnu3OFghcA>?		NEC5NnZKSzVyPU[zMlI1KG6P	MVWyOFUyQTl7NR?=
JURKAT	MoHlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NF6xWGc4OiCq		NF3rNHVKSzVyPUOuOlUhdk1?	MmW5NlQ2OTl7OUW=
MOLT-4	Ml7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHjPdFM4OiCq		NXf1fWtsUUN3ME23MlM6KG6P	Ml22NlQ2OTl7OUW=
REH	MkDaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVXzOmlsPzJiaB?=		NWf6VG81UUN3ME2xOk4xOSCwTR?=	MVGyOFUyQTl7NR?=
NALM-6	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVu3NkBp		MkO1TWM2OD1zLke4JI5O	M1z3cVI1PTF7OUm1
RS 4;11	NXz1TFczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MlfZO\|IhcA>?		MofpTWM2OD12LkO4JI5O	MYKyOFUyQTl7NR?=
697	M{PzR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFzib5E4OiCq		MoLETWM2OD15ND6yPEBvVQ>?	MV6yOFUyQTl7NR?=
SIL-ALL	NIr1cVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MmX6O\|IhcA>?		M1HSZmlEPTB;Nz6yJI5O	NYjLRZQzOjR3MUm5PVU>
CEM	M{fx[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIn1dJU4OiCq		MYLJR\|UxRTVwNEKgcm0>	MlzHNlQ2OTl7OUW=
P12	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NWXHZZpRPzJiaB?=		MnHTTWM2OD14LkO3JI5O	MojuNlQ2OTl7OUW=
NALM-16	MnLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVW3NkBp		Ml3kTWM2OD15Nz63N{BvVQ>?	M2PucFI1PTF7OUm1
Y79	MUPBdI9xfG:\|aYOgRZN{[Xl?	MUSxMVUxKG6P	NH\ESWoyOi9{NDDo	NFXnb3BFVVOR	MmjWbY5lfWOnZDDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU	MmrpNlQ{PjZ4NkW=
WER-Rb-1	M3nKdmFxd3C2b4Ppd{BCe3OjeR?=	MoDhNU02OCCwTR?=	MmPNNVIwOjRiaB?=	MmriSG1UVw>?	Mn;wbY5lfWOnZDDhdI9xfG:\|aYOge4hq[2hiY3HuJIJmKGWwaHHuZ4VlKGK7IFjU	NIH6ZZgzPDN4Nk[2OS=>
G7	NVrIbXVVT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3LFfGlEPTB;Mz6zJI5O	Ml\GNlQzODR5M{O=
G166	NYDLcpc1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRTdwMDDuUS=>	NVHRSm5qOjR{MES3N\|M>
CB660	M{\HNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWjMNoU2UUN3ME22MlQhdk1?	NHnZSo0zPDJyNEezNy=>
CB1117	M4PoVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHPKTGJKSzVyPUG1MlYhdk1?	NV70VIwyOjR{MES3N\|M>
KB-3-1	NWTkdXpoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3XJZmlEPTB;MT60PEDDuSByLkWzJI5O	M4W3VVI{QTZ{NES1
KB-8-5-11	NF[zfoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXzpbZBSUUN3ME21MlAyKMLzIEKuNFEhdk1?	MnnsNlM6PjJ2NEW=
KB-C-1	NVrGU5pPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f0bWlEPTB;MU[uO\|YhyrFiND61NUBvVQ>?	NWf2fnVUOjN7NkK0OFU>
KB-V-1	M2TTfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{DDNmlEPTB;MkixMlI1KMLzIEOxMlU4KG6P	MkfSNlM6PjJ2NEW=
OVCAR-8	NVv1e2hrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHjLXW9KSzVyPUeuNVkhyrFiMz62NEBvVQ>?	MWqyN\|k3OjR2NR?=
NCI-ADR-RES	NFTMXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LiWGlEPTB;MUK3N{4{OCEEsTCxPVEvOjBibl2=	MkLnNlM6PjJ2NEW=
MCF7	NET4T\|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3jHVmlEPTB;NT6xNUDDuSBzLkS3JI5O	NFrSOpEzOzl4MkS0OS=>
MCF7-FLV1000	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mle5TWM2OD1\|OUOuNVghyrFiN{SuPFMhdk1?	NUnTRVFTOjN7NkK0OFU>
S1	MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXCTWM2OD1{ND6zNEDDuSB2Lke1JI5O	M4j2SVI{QTZ{NES1
S1-M1-80	NYjmPG93T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1XIU2lEPTB;Mk[xMlA3KMLzIES4MlI2KG6P	M13J[VI{QTZ{NES1
CORL-23/P	NYLvboVHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGD0V\|NKSzVyPUSuN\|ghyrFiMT6yOUBvVQ>?	M{nUOFI{QTZ{NES1
CORL-23/R	M1XzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3vB[WlEPTB;NT6xOkDDuSBzLkizJI5O	M4jzO\|I{QTZ{NES1
NIH3T3	M4m0WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoLmTWM2OD12MD62NEDDuSB2Lkm3JI5O	MnrvNlM6PjJ2NEW=
NIH3T3-G185	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3vUWWlEPTB;MkSxN{41OCEEsTC0NlMvPjZibl2=	NGS5S4szOzl4MkS0OS=>
pcDNA-HEK293	M1HubGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkPuTWM2OD1{Lke1JOKyKDBwNkegcm0>	M3jMdlI{QTZ{NES1
MDR19-HEK293	M4nH[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXvJR\|UxRTh3LkWwJOKyKDF\|Lk[3JI5O	M1HRSlI{QTZ{NES1
R482-HEK293	Mme0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFH2e\|NKSzVyPUK1Mlk4KMLzIESuPVUhdk1?	NVTZb3lzOjN7NkK0OFU>
MRP1-HEK293	NUS4OIlbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEHrWmhKSzVyPUKuPVkhyrFiMT60PUBvVQ>?	Moi4NlM6PjJ2NEW=
SF188	M2rZe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MUKxNE0yODBibl2=	NH\4cowzPC17NjDo	NXrw[VU{TE2VTx?=	NELJT4pqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CClb37j[Y51emG2aX;uMUBl\XCnZHXueEBu[W6wZYK=	Mn3vNlM5QDd4NEW=
T98G	NF\YPGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnPDNVAuOTByIH7N	NWPmfI17OjRvOU[gbC=>	M4Dh[2ROW09?	MmSwbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iY3;uZ4VvfHKjdHnvck0h\GWyZXTlcpQhdWGwbnXy	MWKyN\|g5PzZ2NR?=
DU145	Mnu4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MljLSG1UVw>?	NUTSdINoUUN3MPMIwFYxKG6P	NIHPbWszOzh6NESyPC=>
LNCaP	NUO5V3kxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=			MkH0SG1UVw>?	M4rHVmlEPTEkiMy3OUBvVQ>?	NHzxcYEzOzh6NESyPC=>
PC3	M37OWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7			NIfqWJpFVVOR	NHnQe41KSzVy4pk8NVc2KG6P	NHLPeIYzOzh6NESyPC=>
RT4	Mn72S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV\JR\|UxRTJ5LkKxJI5O	MWGyN\|c6OjZ\|OR?=
5637	NWe4RWFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrKc49KSzVyPUS1MlQ4KG6P	NUPhfHNFOjN5OUK2N\|k>
T24	M{LtbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MonsTWM2OD15OT6xNkBvVQ>?	NECzT3AzOzd7Mk[zPS=>
MCF7	NIPiSYJHfW6ldHnvckBCe3OjeR?=	MlOxNVAxKG6P	NWnEO\|h5OSCq	NYTqUnVYTE2VTx?=	MofTdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:owrDHdoVjOS{EoGPnb\|EtyqCSc{KsxsBU\XKyaX7hN{wh[W6mwrDXbZNxOg>?	NWLNV5dXOjN5N{CyOFQ>
KB-V1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUK4TmxGUUN3ME2zMlkzKM7:TR?=	NWfyRYVpOjN3OUOxPVY>
Hec50co	NHzqZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTVibl2=	MmHsNlMyPDZ4OEe=
MDA-MB-468	MUXBdI9xfG:\|aYOgRZN{[Xl?	MkTmNU82NzFyIH7N	Ml7SNlQwPDhxN{KgbC=>	NHTkdI1FVVOR	M{Kz[olv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NGjwT3czOzF2NEK5OC=>
MCF10A	MXrBdI9xfG:\|aYOgRZN{[Xl?	NWLoc49NOS93L{GwJI5O	MoL1NlQwPDhxN{KgbC=>	MVTEUXNQ	M3u3bIlv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NIXZflIzOzF2NEK5OC=>
Huh-7	M2HTNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MoC2NU8yOC9zMECvNVAxOCCwTR?=	M1TscVQ5KGh?		MVPk[YNz\WG\|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIRwe2VvZHXw[Y5l\W62bIm=	MVGyNlc1PTV6Nx?=
Daoy	M4LQemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NVnoNoxiOS56N{WtNlQxKG6P	MXe3NkBp	NIL3[W1FVVOR	NWHCfpNVUUN3ME21JI5O	MoLkNlI{QTB{N{m=
ONS-76	NWf4doJyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NXq2SmJHOS56N{WtNlQxKG6P	NWPXVW16PzJiaB?=	NX31NYNHTE2VTx?=	M3rZUWlEPTB;Nz61JI5O	NXrGXFl3OjJ\|OUCyO\|k>
SUM 149	NVzQdJJLT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MXewMVExOCCwTR?=	NH3IPZE4OiCq		M{\INIlvcGmkaYTzJJRp\SClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7hdi=>	MlG4NlI{ODl7M{m=
MDA-MB-231	MkPUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M3HlVFAuOTByIH7N	MWq3NkBp		NV71S2lwcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NHvoNVEzOjNyOUmzPS=>
HR5	NYi5ZZVTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3iO24xNTFyMDDuUS=>	NGLWcIM4OiCq		Mk[4bY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	M2nZbFIzOzB7OUO5
BT-474-M1	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX2wMVExOCCwTR?=	M2DOVVczKGh?		MVfpcohq[mm2czD0bIUh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wYYK=	NHT6NYQzOjNyOUmzPS=>
AU565	NWT5WHFbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MV:wMVExOCCwTR?=	NWjBVnBIPzJiaB?=		NVjldo5PcW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NU\FNHkzOjJ\|MEm5N\|k>
T47D	MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{fJXVAuOTByIH7N	M33wVlczKGh?		NUX0O4Z6cW6qaXLpeJMhfGinIHPlcIwhfmmjYnnsbZR6KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoFz	NVnXdYpSOjJ\|MEm5N\|k>
MCF7	NILvPJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXrCfYRrOC1zMECgcm0>	Mn\KO\|IhcA>?		MoLtbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnHy	MkDkNlI{ODl7M{m=
HCT116p53(+/+)	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MUKxNE0yODByIH7N	NF2wcHozPC92ODDo		NXXtOI1HcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGOxbYDs[ZRmdHliYYSgNlUhdk1?	MkixNlIzPjJzN{G=
HCT116p53(-/-)	NYDndld2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknsNVAuOTByMDDuUS=>	MkCyNlQwPDhiaB?=		M{XrbolvcGmkaYTzJINmdGxicILvcIln\XKjdHnvckBkd22ybHX0[Yx6KGG2IEK1JI5O	NUHLdIZVOjJ{NkKxO\|E>
HeLa	M3raXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M3;YS\|ExNTFyMDDuUS=>	M4jYblQ5KGh?	NGPRW4JFVVOR	NWrOXJF6UUN3ME21Nk46KG6P	NWLkTmFTOjJyOECyN\|U>
HeLa	NUe4d4x4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M124XFExNTFyMDDuUS=>	NXf3fpBPPzJiaB?=	NVz0UI1ITE2VTx?=	NIX1bJFKSzVyPUWwMlUhdk1?	NXf2[IR3OjJyOECyN\|U>
GBC	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVi3NkBp		NEfETJBKSzVyPUG0Mlc5KG6P	M2\wXlIyQTZ3N{O5
GB-CL-1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXfMe3NvPzJiaB?=		NIXGUXFKSzVyPUWuNlIhdk1?	MorBNlE6PjV5M{m=
Mz-ChA-2	M4PQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Mk\2O\|IhcA>?		MkjqTWM2OD1\|LkOxJI5O	NFHwXGwzOTl4NUezPS=>
TGBC1-TKB	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		Moi1NVQ1KGh?		Ml3uTWM2OD14LkeyJI5O	Mn;oNlE6PjV5M{m=
Wittier	M3;6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NF72U2o4OiCq		NW\4Z\|FoUUN3ME2zMlI3KG6P	MWmyNVk3PTd\|OR?=
H-1	NE[x[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{fWSVczKGh?		M{jnSmlEPTB;OT61OEBvVQ>?	M4nDcFIyQTZ3N{O5
HuH-28	NGjhSG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		Mn3sO\|IhcA>?		MUnJR\|UxRTFzLkG5JI5O	M2LSd\|IyQTZ3N{O5
NEC	MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NF7F[oM4OiCq		M{TYb2lEPTB;OT65PEBvVQ>?	NUnPNIlWOjF7NkW3N\|k>
REB	M{C5cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		M{LLV\|czKGh?		MUHJR\|UxRTF\|LkWxJI5O	NH7sVXQzOTl4NUezPS=>
CC-LP-1	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NFz0b4I4OiCq		NF\hfYVKSzVyPUWuPFQhdk1?	Mn[5NlE6PjV5M{m=
CC-SW-1	M{npSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmfCO\|IhcA>?		M1r3NmlEPTB;OT61OUBvVQ>?	Mor4NlE6PjV5M{m=
EGI-1	NEPzc2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MknqO\|IhcA>?		MUnJR\|UxRTFyLkeyJI5O	NWPCRZYyOjF7NkW3N\|k>
Sk-ChA-1	NHTmUYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M{jR[\|czKGh?		M1;STWlEPTB;MUeuNkBvVQ>?	MlfSNlE6PjV5M{m=
TFK-1	MmT1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		MVq3NkBp		NVHM[5RmUUN3ME2xN{41PSCwTR?=	NWLUTJJLOjF7NkW3N\|k>
786-O	M1vReGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MX21MVgxKG6P	M2nhbVk3KGh?	M4LBeGhEdA>?	NYTZVWNKe3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	Mm\iNlE3PDJ\|N{S=
A498	NHnxPIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MnuxOU05OCCwTR?=	NH;WUVU6PiCq	M1;UZ2hEdA>?	NXHuRWVke3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	M17zbVIyPjR{M{e0
ACHN	NF7RUoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWG1MVgxKG6P	MmjTPVYhcA>?	M13ldGhEdA>?	M4K4b5N2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	MUWyNVY1OjN5NB?=
Caki-1	M2[5Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MlzWOU05OCCwTR?=	Moi1PVYhcA>?	M1zMR2hEdA>?	M3XDdJN2eHC{ZYPz[ZMhfGinIIDyc4xq\mW{YYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZIhf2m2aDDJR\|UxyqC4YXz1[ZMhd2ZiMjD0c{AzOCCwTR?=	NHWxRoszOTZ2MkO3OC=>
SN12C	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M1nrdFUuQDBibl2=	MUe5OkBp	M3vhWWhEdA>?	NV7HNJd4e3WycILld5NmeyC2aHWgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meiC5aYToJGlEPTEEoI\hcJVmeyCxZjCyJJRwKDJyIH7N	M{HGRlIyPjR{M{e0
HMC-1.1	NF[yS2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NX3ubnY1OS1zMECwJI5O	MUO3NkBp		Ml7kbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	NYPKOZp1OjF{NEKxPFk>
HMC-1.2	NXWzUnZkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MnjnNU0yODByIH7N	MXS3NkBp		MkLEbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5m	MWqyNVI1OjF6OR?=
C2	M1PHU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnjMNU0yODByIH7N	NVfXUHJlPzJiaB?=		NFu0VWRqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmV?	MlW4NlEzPDJzOEm=
CHP-212	Mn30S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXuxMVEzPSCwTR?=	NUjjfIh1OjRvMUKwJIg>		MmrQbY5pcWKrdIOgeIhmKGOnbHygdJJwdGmoZYLheIlwdiCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZR?=	MnvhNlEyPjl{NEK=
IMR-32	M3PaWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXf3[GhoOS1zMkWgcm0>	NED0b\|kzPC1zMkCgbC=>		NFnHd5NqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	NUn1W3VkOjFzNkmyOFI>
Kelly	NYjrenBHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NVGxWllTOS1zMkWgcm0>	MXWyOE0yOjBiaB?=		MVfpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MVqyNVE3QTJ2Mh?=
SH-EP	NV\pZ4ttT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M1PPe\|EuOTJ3IH7N	MV[yOE0yOjBiaB?=		NEPL[GtqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MWmyNVE3QTJ2Mh?=
SH-SY5Y	MlOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M{DkUVEuOTJ3IH7N	NFXtSVUzPC1zMkCgbC=>		M4\rdYlvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	M1;yeVIyOTZ7MkSy
SK-N-AS	NX3sdpE3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NF3w[oIyNTF{NTDuUS=>	MX2yOE0yOjBiaB?=		NETONnVqdmirYnn0d{B1cGViY3XscEBxem:uaX\ldoF1cW:wIHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7l	MWGyNVE3QTJ2Mh?=
SK-N-BE	NGG1[5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NF;DV\|EyNTF{NTDuUS=>	NITaR\|EzPC1zMkCgbC=>		MXvpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	MkjHNlEyPjl{NEK=
KG1	MoL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmfGNU8yOC9zMECgcm0>	NGfYclk4OiCq	M3Tsb2ROW09?	M1nOfolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnW=	MVSxPVQ2QDN3OB?=
U937	NETt[WRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NV:3RmxQOS9zMD:xNFAhdk1?	M{LRWVczKGh?	MXnEUXNQ	MXPpcohq[mm2czD0bIUh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6n	NXX2XpZxOTl2NUizOVg>
CAL62	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MX6wMlEuOTByIH7N	MlrqO\|IhcA>?	Ml2ySG1UVw>?	NF7GOmJGSzVyPUGuOEBvVQ>?	M1\iZ\|E6OjJ\|NUWz
OCUT-1	M{HZNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mnj3NE4yNTFyMDDuUS=>	M4i3bVczKGh?	NFXXdo9FVVOR	MWXFR\|UxRTJwMzDuUS=>	MlXvNVkzOjN3NUO=
8505C	M2Hte2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MWKwMlEuOTByIH7N	M13xVVczKGh?	NILNbZlFVVOR	NGmzcndGSzVyPUOuNkBvVQ>?	MmD1NVkzOjN3NUO=
ACT-1	M1\GPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MnHqNE4yNTFyMDDuUS=>	MkDXO\|IhcA>?	NWLiNotjTE2VTx?=	MYfFR\|UxRTVwNDDuUS=>	NVvkfZNqOTl{MkO1OVM>
SW1736	MlzGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWwMlEuOTByIH7N	MV23NkBp	M{jTcGROW09?	M3nKfWVEPTB;NT62JI5O	MkHhNVkzOjN3NUO=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	pro-caspase-8 / cleaved caspase-8 / cleaved caspase-3 / cleaved caspase-9; PubMed: 27699933 Cancer Sci PLKi‐induced caspase activation. HeLa cells were treated with BI 2536 (10 nmol/L), BI 6727 (68 nmol/L), or GSK461364 (11 nmol/L), and HCT 116 cells were treated with BI 2536 (20 nmol/L), BI 6727 (70 nmol/L), or GSK461364 (12 nmol/L) for 48 h. The levels of cleaved caspase (CASP)‐3, ‐8, and ‐9 were examined by Western blot analysis. p-HH3 / PARP / Myc / p-Myc; PubMed: 24771642 Clin Cancer Res Western blotting showing more mitotic arrested (shown by phospho-histone H3) and apoptotic (shown by PARP) cells as well as lower MYC levels in LNCaP-Pim1 cells after BI 2536 treatment compared with LNCaP-Neo cells. The difference is obvious at lower dose of BI 2536 (10 nM). Both total MYC expression and phosphor-MYC levels were lower in Pim1 cells than Neo cells after BI 2536 treatment. pMEK / MEK / pERK / ERK / pRSK1 / RSK1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and activation of components of the MEK-ERK-RSK1 pathway in MKN45 and MKN74 cancer cells treated with BI 2536 and BI 6727 for 24 and 48 hours, respectively. pPlk1 / Plk1 / pMyt1; PubMed: 28430578 Oncotarget (A) and (B) Western blot analysis of the expression and phosphorylation of Plk1, and phosphorylation of Myt1 in the CSC-like and cancer cells after treatment with BI 2536 and BI 6727 for 24 and 48 hours, respectively. Aurora B / pAurora B / pAurora C / pH3 / Cyclin B1 / Securin / pBcl-XL / MPM2; PubMed: 25169932 Mol Oncol Western blot analysis of cells treated for 24 h with the indicated inhibitor concentrations. Cell lysates were immunoblotted for Plk1, Phospho-Aurora B (T232)/Aurora C (T198), Aurora B, histone H3 phosphorylated at S10 (pH3), Cdk1, Cyclin B1, Securin, Phospho-Bcl-XL, Induced myeloid leukemia cell differentiation protein Mcl-1, MPM-2 and β-Actin. Left (Hela cells); Right (HUVEC)	27699933 24771642 28430578 25169932
Immunofluorescence	p-H2AX / propidium iodide; PubMed: 22309939 Breast Cancer Res Apoptotic images of the cells after BI 2536 treatment, as revealed by HCS (high-content screening) instrument (×10) with phospho-H2AX antibody or PI (propidium iodide) intake. Pericentrin / α-tubulin; PubMed: 21772266 Nat Commun MEFs were labelled using Plk1, pericentrin and α-tubulin antibodies and 4,6-diamidino-2-phenylindole for the analysis by immunofluorescence microscopy. Representative examples of BI 2536-treated and control MEFs are depicted. Scale bar, 5 μm.	22309939 21772266
Growth inhibition assay	Cell viability; PubMed: 21772266 Nat Commun Proliferative activity of MEFs at different BI 2536 concentrations (25–250 nM; means±s.d., n=3, for each concentration). P<0.05, P<0.01, **P<0.001, Student's t-test, unpaired and two-tailed.	21772266

体内研究

BI 2536静脉注射给药多种移植瘤模型，每周一次或两次，效果都很好，通过使细胞周期停滞而抑制细胞增殖，随后诱导肿瘤细胞死亡。BI 2536按 50 mg/kg剂量处理HCT 116移植瘤，每周一次或两次，显著抑制肿瘤生长，T/C 分别为15%和0.3%。BI 2536每周处理两次BxPC-3和A549模型，也显著抑制肿瘤生长，T/C分别为5% 和14%。^[1]

激酶实验： ^[1]	- 合并体外Plk1激酶实验: 重组人Plk1 (1-603残基) 作为氮端，携带杆状病毒表达系统的GST-标记的融合蛋白通过亲和层析，使用谷胱甘肽-琼脂糖而纯化。在梯度稀释的BI 2536存在时，使用 20 ng 重组激酶，及10 μg牛奶中的酪蛋白作为底物进行Plk1 酶活性实验。在终体积为60 μL 的混合物(15 mM MgCl₂, 25 mM MOPS [pH 7.0], 1 mM DTT, 1% DMSO, 7.5 mM ATP, 0.3 μCi γ-³³P-ATP)中30^oC下进行激酶反应45分钟。加入 125 μL 冰冻的5% TCA终止反应。沉淀物转移到混合酯纤维素的多屏过滤板上，使用1% TCA冲洗实验板，然后利用放射性进行测量。绘制剂量反应曲线，而计算IC50值。
细胞实验：^[1]	- 合并 Cell lines: HeLa, A43, SKOV-3, HT-29, K562, A549, Saos-2, MCF7, HCT116, COLO 205, Hep G2, Raji, PC-3,等等 Concentrations: 溶于DMSO, 终浓度为~1 μM Incubation Time: 24,和72小时 Method: 使用不同浓度BI 2536处理细胞24和72小时。在荧光分光光度计中测量Alamar Blue染料转换而测定细胞生长。为了测定培养基中DNA含量，细胞悬液在80%乙醇中混合, 使用溶于PBS的0.25% Triton X-100处理5分钟，然后与0.1% RNase 和溶于PBS的 10 μg/mL碘化丙啶在室温下温育20分钟。通过流式细胞仪分析而测定细胞周期谱。 (Only for Reference)
动物实验：^[1]	- 合并 Animal Models: 皮下注射HCT 116, NCI-H460, 或A549 细胞的雌性BomTac:NMRI-Foxn1nu 小鼠 Dosages: ~50 mg/kg Administration: 静脉注射，每周一到两次 (Only for Reference)

参考文献

溶解度 (25°C)

体外	DMSO	21 mg/mL (40.25 mM)
	Water	Insoluble
	Ethanol	'100 mg/mL
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 30% PEG 400+0.5% Tween 80+5% Propylene glycol	15mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BI 2536 SDF

分子量	521.66
化学式	C₂₈H₃₉N₇O₃
CAS号	755038-02-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02215044	Terminated	Drug: BI 2536 intravenous\|Drug: Gemcitabine intravenous	Pancreatic Neoplasms	Boehringer Ingelheim	June 2007	Phase 1
NCT02211833	Completed	Drug: BI 2536\|Drug: Pemetrexed	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	October 2006	Phase 1
NCT00701766	Completed	Drug: BI 2536	Leukemia Myeloid Acute	Boehringer Ingelheim	October 2006	Phase 2
NCT00706498	Completed	Drug: BI 2536	Prostatic Neoplasms	Boehringer Ingelheim	September 2006	Phase 2
NCT00376623	Completed	Drug: BI 2536	Carcinoma Non-Small-Cell Lung	Boehringer Ingelheim	July 2006	Phase 2
NCT02211872	Completed	Drug: BI 2536 BS intravenous	Neoplasms	Boehringer Ingelheim	August 2004	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
We need to use BI 2536 in preclinical studies using mice, how to formulate the inhibitor for this in vivo study?
回答：
For in vivo study, DMSO should not be more than 5% because the toxicity. You can formulated BI2536 in hydrochloric acid (0.1 N), and diluted with 0.9% NaCl for animal study according to the reference :( Supplemental Data) http://linkinghub.elsevier.com/retrieve/pii/S0960-9822(06)02671-6

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

选择性强的Plk抑制剂

GSK461364 : Plk1-selective, K_i=2.2 nM.
用于临床的Plk抑制剂

Rigosertib (ON-01910) : Phase III for Myelo Dysplastic Syndrome (MDS).
最新的Plk抑制剂

Ro3280 ^New : Potent, highly selective inhibitor of Polo-like kinase 1 (PLK1) with IC50 of 3 nM.
经典的Plk抑制剂

Volasertib (BI 6727) : Highly potent Plk1 inhibitor with IC50 of 0.87 nM and in phase II trials.

研究领域

产品类型

BI 2536

客户使用Selleck生产的BI 2536发表文献160篇：

产品安全说明书

PLK抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BI 2536 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2020-05-15)

技术支持

常见问题及建议解决方法

PLK Signaling Pathway Map

PLK Inhibitors with Unique Features

相关PLK产品